AR047436A1 - Compuesto de piperidin-2-ona1,6-disubstituido, solucion oftalmica que lo comprende, producto farmaceutico que comprende esta ultima y uso del compuesto para preparar dicha solucion oftalmica - Google Patents

Compuesto de piperidin-2-ona1,6-disubstituido, solucion oftalmica que lo comprende, producto farmaceutico que comprende esta ultima y uso del compuesto para preparar dicha solucion oftalmica

Info

Publication number
AR047436A1
AR047436A1 ARP050100195A ARP050100195A AR047436A1 AR 047436 A1 AR047436 A1 AR 047436A1 AR P050100195 A ARP050100195 A AR P050100195A AR P050100195 A ARP050100195 A AR P050100195A AR 047436 A1 AR047436 A1 AR 047436A1
Authority
AR
Argentina
Prior art keywords
ophthalmic solution
compound
container
general formula
configuration
Prior art date
Application number
ARP050100195A
Other languages
English (en)
Spanish (es)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR047436A1 publication Critical patent/AR047436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP050100195A 2004-01-22 2005-01-20 Compuesto de piperidin-2-ona1,6-disubstituido, solucion oftalmica que lo comprende, producto farmaceutico que comprende esta ultima y uso del compuesto para preparar dicha solucion oftalmica AR047436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/763,702 US6977260B2 (en) 2004-01-22 2004-01-22 Piperidinyl prostaglandin E analogs

Publications (1)

Publication Number Publication Date
AR047436A1 true AR047436A1 (es) 2006-01-18

Family

ID=34795110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100195A AR047436A1 (es) 2004-01-22 2005-01-20 Compuesto de piperidin-2-ona1,6-disubstituido, solucion oftalmica que lo comprende, producto farmaceutico que comprende esta ultima y uso del compuesto para preparar dicha solucion oftalmica

Country Status (11)

Country Link
US (1) US6977260B2 (cg-RX-API-DMAC7.html)
EP (1) EP1722795B1 (cg-RX-API-DMAC7.html)
JP (1) JP4740883B2 (cg-RX-API-DMAC7.html)
AR (1) AR047436A1 (cg-RX-API-DMAC7.html)
AT (1) ATE394101T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005209209B2 (cg-RX-API-DMAC7.html)
CA (1) CA2553387C (cg-RX-API-DMAC7.html)
DE (1) DE602005006534D1 (cg-RX-API-DMAC7.html)
ES (1) ES2303672T3 (cg-RX-API-DMAC7.html)
TW (1) TWI348370B (cg-RX-API-DMAC7.html)
WO (1) WO2005072735A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326716B2 (en) * 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
WO2006047466A2 (en) * 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3220156C2 (de) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
IT1225716B (it) * 1988-10-26 1990-11-22 Esacontrol Spa Dispositivo per la protezione dei rele' di binario dai disturbi elettrici
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
DE4318713C1 (de) * 1993-06-07 1994-09-15 Daimler Benz Ag Zahnräderwechselgetriebe der Vorgelegebauart
EP1513589B1 (en) * 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (en) 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
JP2006527189A (ja) * 2003-06-06 2006-11-30 アラーガン、インコーポレイテッド ピペリジニルプロスタグランジンe類似体
US6747037B1 (en) * 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Also Published As

Publication number Publication date
HK1099203A1 (en) 2007-08-10
CA2553387C (en) 2013-04-02
US6977260B2 (en) 2005-12-20
WO2005072735A1 (en) 2005-08-11
TWI348370B (en) 2011-09-11
JP4740883B2 (ja) 2011-08-03
US20050164990A1 (en) 2005-07-28
ATE394101T1 (de) 2008-05-15
JP2007520489A (ja) 2007-07-26
ES2303672T3 (es) 2008-08-16
CA2553387A1 (en) 2005-08-11
AU2005209209B2 (en) 2012-03-08
DE602005006534D1 (de) 2008-06-19
TW200533350A (en) 2005-10-16
EP1722795A1 (en) 2006-11-22
AU2005209209A1 (en) 2005-08-11
EP1722795B1 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
UY28132A1 (es) Derivados de pirrolopirimidina
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
TNSN07471A1 (en) Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
HRP20090459T1 (hr) Aminofenil derivati kao novi inhibitori histonskih deacetilaza
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
CA2485850A1 (en) 8-azaprostaglandin analogs as agents for lowering intraocular pressure
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
AR060237A1 (es) Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
AR035285A1 (es) Formulaciones en combinacion de derivados de1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion.
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
AR119143A1 (es) Compuesto de 1h-pirrolo[3,2-b]piridin-5-ilo, composición farmacéutica que lo comprende y su uso para fabricar un medicamento
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Legal Events

Date Code Title Description
FA Abandonment or withdrawal